Abstract

Doc number: 144

Abstract

Background: Angelica Sinensis (AS), a folk medicine, has long been used in ergogenic aids for athletes, but there is little scientific evidence supporting its effects. We investigated whether AS induces hypertrophy in myotubes through the phosphatidylinositol 3-kinase (PI3K)/Akt (also termed PKB)/mammalian target of the rapamycin (mTOR) pathway.

Methods: An in vitro experiment investigating the induction of hypertrophy in myotubes was conducted. To investigate whether AS promoted the hypertrophy of myotubes, an established in vitro model of myotube hypertrophy with and without AS was used and examined using microscopic images. The role of the PI3K/Akt/mTOR signaling pathway in AS-induced myotube hypertrophy was evaluated. Two inhibitors, wortmannin (an inhibitor of PI3K) and rapamycin (an inhibitor of mTOR), were used.

Result: The results revealed that the myotube diameters in the AS-treated group were significantly larger than those in the untreated control group (P < 0.05). Wortmannin and rapamycin inhibited AS-induced hypertrophy. Furthermore, AS increased Akt and mTOR phosphorylation through the PI3K pathway and induced myotube hypertrophy.

Conclusion: The results confirmed that AS induces hypertrophy in myotubes through the PI3K/Akt/mTOR pathway.

Details

Title
Angelica Sinensis promotes myotube hypertrophy through the PI3K/Akt/mTOR pathway
Author
Yeh, Tzu-Shao; Hsu, Cheng-Chen; Yang, Suh-Ching; Hsu, Mei-Chich; Liu, Jen-Fang
Pages
144
Publication year
2014
Publication date
2014
Publisher
Springer Nature B.V.
e-ISSN
1472-6882
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
1526072272
Copyright
© 2014 Yeh et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.